How Sarcopenia (Muscle Loss with Age) Is Now Considered a Disease

Sarcopenia, the progressive loss of skeletal muscle mass and strength that accompanies aging, was formally recognized as a distinct disease in 2016, when the World Health Organization assigned it its own diagnostic billing code (ICD-10-CM M62.84).

That reclassification shifted sarcopenia from an inevitable, unremarkable part of growing old into a condition that can be screened for, diagnosed, coded, treated and, increasingly, targeted by drug developers.

The consequences of that shift are still unfolding across clinics, insurance systems and pharmaceutical pipelines a decade later.

The Reclassification That Changed Everything

For most of modern medicine’s history, the muscle wasting that comes with age was treated as background noise, a fact of biology too diffuse to code, bill, or study with the same rigor applied to osteoporosis or diabetes.

That changed on October 1, 2016, when sarcopenia received its own ICD-10-CM code, M62.84, placing it formally within Chapter 13 of the classification system, alongside other diseases of the musculoskeletal system and connective tissue.

Researchers writing in the Journal of the American Medical Directors Association at the time called the code assignment recognition of sarcopenia as an independent condition, not merely a symptom of aging or of some other underlying illness.

The practical effect took years to materialize. A billing code alone does not create clinical infrastructure, and physicians writing in PubMed observed that the new code represented a major step forward in recognizing sarcopenia as a disease, one expected to increase the availability of diagnostic tools and pharmaceutical industry investment in treatments.

That prediction has largely held. What began as an administrative change has since pulled sarcopenia into mainstream geriatric medicine, endocrinology, oncology and, most recently, the obesity drug conversation.

In short: Sarcopenia stopped being treated as an unavoidable side effect of aging once it received a formal ICD-10-CM code (M62.84) in 2016. That reclassification created a billable diagnosis, standardized screening pathways, and commercial incentive for drug development, transforming muscle loss from a vague complaint into a condition with defined criteria, treatment protocols, and a growing research pipeline.

Why Muscle Loss Was Ignored for So Long

The dominant assumption for decades held that shrinking muscles were simply what happened after sixty, in the same category as graying hair or wrinkling skin: universal, cosmetic in consequence, and not worth a diagnosis. That framing obscured a set of measurable physiological changes with real clinical stakes.

Skeletal muscle mass declines by roughly 6 percent per decade beginning in midlife, according to prospective studies cited in orthopedic rehabilitation literature, and the decline accelerates sharply after age 60.

The term itself is relatively young. Sarcopenia, derived from the Greek for poverty of flesh, was coined by Irwin Rosenberg in 1989 to describe age-related muscle loss as a distinct phenomenon worth naming. It took more than two decades from that naming for the medical establishment to agree on how to measure the condition, and another six years after that for it to receive formal disease status.

The gap illustrates something common to geriatric medicine generally: conditions that affect primarily older adults, and that present gradually rather than acutely, tend to be pathologized far later than conditions with sharper clinical presentations.

How Sarcopenia Is Actually Diagnosed Today

Recognition as a disease required something sarcopenia had never had: a standardized way to measure it. The most widely used framework internationally comes from the European Working Group on Sarcopenia in Older People, whose revised 2019 consensus (known as EWGSOP2) reorganized diagnosis around a sequence clinicians call Find-Assess-Confirm-Severity.

The pathway works like this. Clinicians first screen for probable sarcopenia using a short questionnaire called SARC-F, or through clinical suspicion when a patient reports difficulty rising from a chair, climbing stairs, or has experienced a recent fall.

Patients who screen positive undergo a strength assessment, typically handgrip strength measured with a dynamometer, or a five-times chair stand test. A diagnosis of probable sarcopenia is confirmed with imaging that quantifies muscle mass directly, most often dual-energy X-ray absorptiometry (DXA), with bioelectrical impedance analysis, CT or MRI used in specialty and research settings. Severity is then graded using physical performance measures such as gait speed.

EWGSOP2’s central departure from earlier frameworks was practical rather than theoretical: it prioritized muscle strength over muscle mass as the primary diagnostic trigger. Grip strength predicts falls, hospitalization, and mortality more reliably than mass alone, and the earlier 2010 EWGSOP criteria, which weighted mass more heavily, tended to overdiagnose the condition.

Lowering the handgrip cutoffs, from 30 kg to 27 kg in men and 20 kg to 16 kg in women under the earlier standard, brought EWGSOP2’s prevalence estimates closer to those produced by competing frameworks such as the Asian Working Group for Sarcopenia (AWGS), the International Working Group on Sarcopenia (IWGS), and the U.S. Foundation for the National Institutes of Health (FNIH) criteria.

That multiplicity of competing definitions remains an underappreciated complication. A 2024 critical evaluation published in Nutrients found that the EWGSOP2’s lowered handgrip cutoffs sit close to those used by other working groups, but that using EWGSOP2’s specific thresholds can still underestimate the true prevalence of the sarcopenic phenotype compared to alternative approaches.

In practice, this means the same patient can receive different diagnoses depending on which criteria a clinician happens to use, an inconsistency that continues to complicate everything from insurance reimbursement to cross-study comparisons of drug trial results.

A comparative study across eight cohorts found sarcopenia prevalence in men dropped from 31.9 percent under the original EWGSOP criteria to 12.0 percent under EWGSOP2, a nearly threefold swing driven entirely by the definitional update rather than by any change in the patients themselves.

Common Misconception: Sarcopenia Is Not the Same as Frailty

Clinicians frequently encounter confusion between sarcopenia and frailty, and the two conditions are related but distinct. Frailty is a broader geriatric syndrome encompassing reduced physiological reserve across multiple systems, including but not limited to muscle.

Sarcopenia is often a contributing driver of frailty, and the two frequently co-occur in the same patient. Still, a person can be sarcopenic without meeting full frailty criteria, and vice versa.

Treating the terms interchangeably, a mistake seen often in both patient-facing content and, occasionally, in clinical documentation, obscures the fact that sarcopenia has its own specific, measurable diagnostic pathway independent of frailty scoring tools like the Fried Frailty Phenotype.

The Scale of the Problem

Global prevalence estimates vary substantially depending on which diagnostic criteria and population are used, which is itself a symptom of the definitional inconsistency described above. A large meta-analysis pooling 35 studies and more than 58,000 participants estimated overall global prevalence at 10 percent in both men and women aged over 60.

Other reviews put the range considerably wider: a systematic review of community-dwelling older adults estimated prevalence in people aged 65 and older at 6 to 22 percent, with the total number of people affected globally projected to reach as high as 500 million by 2050.

Regional and setting-specific numbers diverge even more sharply, with prevalence in post-acute hospital and rehabilitation wards climbing to 26.9 to 58 percent, and as high as 50.9 to 60.2 percent in daycare facility populations, reflecting how much illness, immobility, and hospitalization accelerate the condition.

The mortality signal is not subtle. A 2023 meta-analysis found sarcopenia associated with a 36 percent increase in all-cause mortality, and separate research has linked the condition to a more than doubled risk of cognitive impairment.

These figures explain why disease status mattered beyond semantics: a condition tied to mortality risk on that scale merits the screening infrastructure, research funding and treatment development that a formal diagnosis unlocks, in a way that a vague reference to getting older never could.

What Is Actually Driving Muscle Loss

Sarcopenia’s underlying biology is more mechanistically complex than the layperson’s shorthand of not exercising enough suggests.

Contemporary research identifies several interacting pathways: anabolic resistance, in which aging muscle becomes progressively less responsive to the protein-synthesis signal delivered by dietary protein and resistance exercise; neuromuscular degeneration, involving the loss of motor neurons and the units of muscle fiber they control; chronic low-grade inflammation, sometimes referred to as inflammaging; hormonal shifts, including declining testosterone, estrogen and growth hormone; and mitochondrial dysfunction within muscle cells themselves.

Systemic regulators including the renin-angiotensin system and specific microRNAs have also drawn increasing research attention as potential intervention targets rather than mere bystanders in the process.

This mechanistic complexity is precisely why sarcopenia proved resistant to a single pharmaceutical fix for so long, and why resistance training and adequate protein intake, unglamorous as they sound, remain the most consistently evidence-backed interventions available. No single pathway explains sarcopenia in every patient, so no single drug target has yet proven universally effective.

The New Complication: GLP-1 Weight-Loss Drugs

The most significant recent development in sarcopenia’s clinical story has nothing to do with elderly patients in nursing homes and everything to do with the explosive popularity of GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound).

These drugs produce weight loss on a scale rarely achieved outside bariatric surgery, but a growing body of 2025 and 2026 research has forced a reckoning over what portion of that lost weight is muscle rather than fat.

Analysis of body composition data from major GLP-1 trials, including the STEP and SURMOUNT programs, indicates that up to 40 percent of weight lost on high-efficacy GLP-1 drugs can be lean body mass. This proportion becomes especially consequential in adults over 65, who typically start with lower baseline muscle mass and reduced capacity to rebuild it.

Clinical observations gathered through 2025 and 2026 has documented an average lean mass decline of 10 to 15 percent in patients losing more than 15 percent of body weight on high-dose GLP-1 therapy, with functional measures such as grip strength and timed chair rises worsening by 5 to 10 percent absent countermeasures.

The clinical response has moved quickly. A joint advisory issued in August 2025 by four American organizations spanning lifestyle medicine, nutrition and obesity medicine recommended consuming 1.2 to 1.6 grams of protein per kilogram of body weight daily during active GLP-1-driven weight loss, given that trial data shows fat-free mass or lean soft tissue accounts for roughly 10 to 25 percent of total weight reduction on these drugs.

Preventive strategy papers now recommend baseline assessment of body composition and muscle function before starting therapy, individualized resistance and multicomponent exercise programs, and periodic reassessment of body composition, strength and physical performance throughout treatment.

The scientific community itself remains divided on how alarmed to be. At the American Diabetes Association’s 2026 Scientific Sessions, the question was debated directly, with Samuel Klein of Washington University arguing that the majority of GLP-1-induced weight loss is fat mass rather than fat-free mass, and that no evidence shows GLP-1-driven weight loss causes frailty or sarcopenia, a position challenged by colleagues who point to the disproportionate lean-mass loss documented in body composition substudies.

A 2026 review in the journal Diabetes & Metabolism took a middle position, concluding that results are largely reassuring for the general population, but that sarcopenia risk becomes a genuine concern in specific subgroups already predisposed to the condition independent of GLP-1 use, including frail older adults and patients with pre-existing low muscle mass.

This is arguably the most consequential development in sarcopenia’s clinical relevance since the 2016 ICD-10-CM code itself. It has pulled the condition out of geriatric wards and into the prescribing decisions of endocrinologists, primary care physicians, and obesity medicine specialists treating patients decades younger than the traditional sarcopenia population, and it has reframed muscle preservation as an active management goal rather than an afterthought during any medically induced rapid weight loss.

Overlooked Point: Sarcopenic Obesity Complicates the Picture Further

A related and frequently underappreciated phenomenon is sarcopenic obesity, the coexistence of excess fat mass with low muscle mass and strength in the same patient. This population is particularly difficult to identify because standard body mass index calculations can mask the underlying muscle deficit entirely; a patient can carry a BMI well within the overweight or obese range while simultaneously meeting diagnostic criteria for sarcopenia.

GLP-1 therapy in this population raises a genuinely difficult clinical tension: the drugs are highly effective at reducing the fat component driving cardiometabolic risk, but without deliberate resistance training and protein intervention, they can simultaneously worsen the muscle deficit that defines the sarcopenia half of the diagnosis.

Treatment: What Actually Works, and What Is Still Experimental

No pharmaceutical agent currently holds regulatory approval specifically for sarcopenia, a fact that surprises many patients given the condition’s disease status. The interventions with the strongest evidence base remain non-pharmacological.

Resistance exercise is the single most evidence-backed intervention available, with progressive resistance training shown to increase muscle strength and, to a lesser degree, muscle mass across virtually every population studied, including frail, hospitalized and institutionalized older adults.

A 2025 expert opinion published in geriatric rehabilitation literature reinforced that therapeutic exercise, including resistance, aerobic and balance training, is recommended by international guidelines to improve muscle mass, muscle strength and physical performance in primary sarcopenia.

Protein intake and leucine-enriched supplementation form the second pillar. Because aging muscle exhibits anabolic resistance, older adults typically require higher protein intake than younger adults to achieve the same muscle-protein synthesis response, a principle now also driving the protein recommendations issued for GLP-1 patients described above.

Pharmacological development remains in an earlier stage but increasingly active, a shift attributable in no small part to the commercial incentive created by the 2016 disease reclassification. Myostatin and activin pathway inhibitors, which target the biological brakes that limit muscle growth, represent the most closely watched drug class.

Bimagrumab, an antibody targeting activin type II receptors, has been studied in combination with semaglutide specifically to test whether it can preserve or build muscle. At the same time, a patient loses fat on a GLP-1 drug, with a 2026 randomized phase 2 trial published in Nature Medicine examining bimagrumab plus semaglutide, alone and in combination, for obesity treatment.

That combination approach, pairing a muscle-preserving agent with a fat-loss agent, may represent the direction future obesity pharmacology moves as the industry absorbs the lean-mass concerns raised by first-generation GLP-1 therapy.

A Practical Framework for Assessing Risk

Readers concerned about their own muscle health, or that of an aging family member, can use a simplified version of the clinical screening logic described above as an early warning framework, without requiring a DXA scan or specialist referral:

Difficulty rising unassisted from a low chair, a noticeably weaker grip when opening jars or shaking hands compared to a few years prior, a slowing walking pace, unintentional weight loss combined with visible loss of muscle definition, and recent unexplained falls are the everyday equivalents of the SARC-F screening questions clinicians use.

Any combination of two or more of these signals, particularly in someone over 60, over 50 with a chronic illness, or anyone undergoing rapid medically induced weight loss, is a reasonable trigger for a conversation with a physician about formal grip strength testing or a referral for body composition assessment.

What This Means Going Forward

Sarcopenia’s transformation from an accepted feature of aging into a coded, billable, actively researched disease has changed the incentives across the entire system responsible for treating it. Insurers now reimburse for a condition that previously had no diagnostic home.

Pharmaceutical developers now have a defined regulatory pathway and patient population to target, one recently expanded by the unexpected commercial pressure created by GLP-1 obesity drugs. Clinicians have standardized, if still imperfect, tools to screen for and grade the condition rather than dismissing early symptoms as ordinary aging.

The unresolved tension is between recognition and consistency. Competing diagnostic frameworks still produce meaningfully different prevalence estimates for the same populations, and no drug has yet earned an indication specifically for sarcopenia itself.

What has changed decisively is the default assumption: muscle loss with age is no longer something patients and physicians are expected to simply accept. It is something with a name, a code, a diagnostic pathway and, increasingly, a research pipeline aimed at slowing or reversing it.

What People Ask